AtriCure (ATRC) to Release Quarterly Earnings on Tuesday

AtriCure (NASDAQ:ATRC) is expected to issue its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $140.50 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.

AtriCure Stock Down 0.5%

Shares of AtriCure stock opened at $36.92 on Tuesday. AtriCure has a 52-week low of $28.29 and a 52-week high of $43.18. The company has a quick ratio of 2.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.84 billion, a P/E ratio of -60.52 and a beta of 1.42. The company has a 50 day moving average of $39.34 and a 200 day moving average of $36.80.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ATRC shares. JPMorgan Chase & Co. boosted their price target on shares of AtriCure from $42.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, January 21st. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. Finally, Canaccord Genuity Group boosted their price target on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AtriCure has an average rating of “Moderate Buy” and a consensus target price of $52.44.

Insider Transactions at AtriCure

In related news, insider Justin J. Noznesky sold 5,166 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total value of $192,640.14. Following the sale, the insider owned 78,798 shares of the company’s stock, valued at approximately $2,938,377.42. This trade represents a 6.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Maggie Yuen sold 3,000 shares of the firm’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $35.72, for a total value of $107,160.00. Following the completion of the sale, the director owned 11,371 shares in the company, valued at $406,172.12. The trade was a 20.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 18,166 shares of company stock valued at $676,378. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its position in shares of AtriCure by 3.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,370 shares of the medical device company’s stock valued at $799,000 after purchasing an additional 765 shares during the period. New York State Common Retirement Fund grew its position in AtriCure by 22.8% during the 2nd quarter. New York State Common Retirement Fund now owns 17,064 shares of the medical device company’s stock worth $559,000 after purchasing an additional 3,171 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of AtriCure by 98.6% during the second quarter. American Century Companies Inc. now owns 33,504 shares of the medical device company’s stock valued at $1,098,000 after buying an additional 16,632 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of AtriCure by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after purchasing an additional 1,230 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in AtriCure in the 3rd quarter valued at approximately $424,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.